1. Home
  2. MDXH vs CODA Comparison

MDXH vs CODA Comparison

Compare MDXH & CODA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDXH
  • CODA
  • Stock Information
  • Founded
  • MDXH 2003
  • CODA 1994
  • Country
  • MDXH Belgium
  • CODA United States
  • Employees
  • MDXH N/A
  • CODA N/A
  • Industry
  • MDXH
  • CODA Industrial Machinery/Components
  • Sector
  • MDXH
  • CODA Industrials
  • Exchange
  • MDXH Nasdaq
  • CODA Nasdaq
  • Market Cap
  • MDXH 84.6M
  • CODA 88.7M
  • IPO Year
  • MDXH 2021
  • CODA N/A
  • Fundamental
  • Price
  • MDXH $2.18
  • CODA $8.16
  • Analyst Decision
  • MDXH Buy
  • CODA Strong Buy
  • Analyst Count
  • MDXH 1
  • CODA 1
  • Target Price
  • MDXH $6.00
  • CODA $11.00
  • AVG Volume (30 Days)
  • MDXH 67.5K
  • CODA 65.1K
  • Earning Date
  • MDXH 08-20-2025
  • CODA 06-16-2025
  • Dividend Yield
  • MDXH N/A
  • CODA N/A
  • EPS Growth
  • MDXH N/A
  • CODA 21.86
  • EPS
  • MDXH N/A
  • CODA 0.30
  • Revenue
  • MDXH $94,507,000.00
  • CODA $22,758,966.00
  • Revenue This Year
  • MDXH $23.51
  • CODA $11.64
  • Revenue Next Year
  • MDXH $17.68
  • CODA $14.53
  • P/E Ratio
  • MDXH N/A
  • CODA $27.34
  • Revenue Growth
  • MDXH 25.46
  • CODA 24.78
  • 52 Week Low
  • MDXH $1.35
  • CODA $5.76
  • 52 Week High
  • MDXH $3.50
  • CODA $9.89
  • Technical
  • Relative Strength Index (RSI)
  • MDXH 58.07
  • CODA 64.18
  • Support Level
  • MDXH $2.13
  • CODA $7.78
  • Resistance Level
  • MDXH $2.32
  • CODA $8.46
  • Average True Range (ATR)
  • MDXH 0.12
  • CODA 0.60
  • MACD
  • MDXH 0.01
  • CODA 0.07
  • Stochastic Oscillator
  • MDXH 76.19
  • CODA 72.99

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

About CODA Coda Octopus Group Inc. Common stock

Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company's operations are organized into two reportable segments: the Products Segment (Marine Technology Business serving the subsea market and PAL, which sells other products (acoustic hydrophones and acoustic materials to a different market); and the Services Segment (Marine Engineering Business). Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.

Share on Social Networks: